NeuroMetrix (NURO) To Launch NC-stat DPNCheck,Targeting Diabetes Market
Over twenty-five million children and adults in the united states—-a little over eight percent of the population have diabetes— Sixty to seventy percent of all people with diabetes will eventually develop peripheral neuropathy—
Welcome to CRWE Newswire () I’m Christina Collins —Diabetic peripheral neuropathy, DPN, leads to numbness, loss of sensation, and sometimes pain in your feet, legs, or hands— It is the most common complication of diabetes—Today’s company highlight is NeuroMetrix Incorporated trading with the symbol NURO —The company announced it expects to meet its planned launch date for its latest product, NC-statDPNCheck, which is a fast, accurate, and quantitative test for the evaluation of systemic neuropathies such as diabetic peripheral neuropathy—The marketing launch will occur during the exhibition at the American Diabetes Association 71st Scientific Sessions in San Diego, CA on June 24 through the 28, 2011–NeuroMetrix is a science-based health care company improving patient care through neurotechnology— The company develops and markets innovative products for the detection, diagnosis, and monitoring of peripheral nerve disorders such as those associated with diabetes and carpal tunnel syndrome—For more information about NeuroMetrix Incorporated, symbol NURO, visit neurometrix.com. I’m Christina Collins with CRWE Newswire
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!
Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. crwenewswire.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers.Our disclaimer (Read more at http://www.crwenewswire.com/disclaimer) is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold crwenewswire.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (CRWE.OB) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period.